Groettrup-Wolfers E

No ORCID on file · 4 papers in corpus · active 2017-2026

Study types

  • article 1
  • other 1

Condition tags

  • endometriosis 2
  • chronic_pelvic_pain 1
2026
Efficacy and Safety of Vilaprisan in the Treatment of Uterine Fibroids: Data from ASTEROID 5, a Phase 3 Multicenter Randomized Controlled Trial.
Journal of clinical medicine ·doi:10.3390/jcm15093246

Background/Objectives: Vilaprisan and ulipristal acetate (UPA) have demonstrated efficacy in treating uterine fibroids (UFs). However, a direct comparison of vilaprisan and UPA has been restricted, to date, to a small phase 2 study. Here, w…

2025
Safety and efficacy of vilaprisan in Japanese women with fibroids: The Phase 3 ASTEROID 8 trial.
Women's health (London, England) ·doi:10.1177/17455057251378954

BackgroundVilaprisan is a selective progesterone receptor modulator with demonstrated efficacy in the management of uterine fibroids (UFs).ObjectivesTo evaluate the safety and efficacy of vilaprisan in Japanese women with UFs and heavy mens…

other 2024
Vilaprisan for the treatment of symptomatic endometriosis: results from a terminated phase 2b randomized controlled trial
F&S reports ·doi:10.1016/j.xfre.2024.03.002

OBJECTIVE: To evaluate the efficacy and safety of 2 doses of vilaprisan vs. placebo in participants with symptomatic endometriosis. DESIGN: Multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2b trial (NCT035733…

article 2017
Efficacy, safety and tolerability of the CCR1 antagonist BAY 86‐5047 for the treatment of endometriosis‐associated pelvic pain: a randomized controlled trial
Acta obstetricia et gynecologica Scandinavica ·doi:10.1111/aogs.13105

INTRODUCTION: Antagonism of CC chemokine receptor type 1 (CCR1) may provide a novel treatment approach for women with symptomatic endometriosis. Studies of CCR1 antagonists in these patients have not been reported. MATERIAL AND METHODS: Wom…